Towards effective targeted therapies in morphea.

Area of Science:

• Dermatology
• Immunology
• Fibrosing skin conditions

Background:

• Morphea is a rare inflammatory fibrosing skin disorder with diverse clinical presentations.
• Severe morphea subtypes cause significant morbidity, necessitating early intervention to prevent permanent damage.
• Lack of consensus classification, validated disease measures, approved therapies, and treatment guidelines pose challenges.

Purpose of the Study:

• To integrate current knowledge on morphea's clinical heterogeneity, immunopathogenesis, and therapeutic data.
• To propose a forward-looking, mechanism-based framework for clinical management.
• To address the limited understanding of morphea's immunopathogenic mechanisms.

Main Methods:

• Literature review integrating clinical heterogeneity, molecular etiopathogenesis, and therapeutic data.
• Analysis of transcriptomic and immunologic profiling studies.
• Review of case series and observational studies on emerging therapies.

Main Results:

• Morphea is characterized as a skin-directed, pro-inflammatory disorder, likely a type 1 interferonopathy.
• Lesional skin shows enrichment of type I interferon pathways, Th1/Th17 cytokines, and B-cell activation.
• Janus kinase (JAK) inhibitors, abatacept, and tocilizumab show encouraging outcomes in specific morphea subtypes.

Conclusions:

• Understanding morphea's immunopathogenesis is crucial for effective treatment.
• Emerging therapies targeting specific pathways show promise, particularly for resistant disease.
• Future precision treatments require expanded knowledge of molecular etiopathogenesis and epidermal-dermal crosstalk.